Intrathecal trastuzumab might thus be a promising treatment for leptomeningeal involvement in HER2-positive breast cancer patients, and further perspective studies have to be done to better determine the efficacy, safety, and tolerability of this approach. The gene discussed is ERBB2; the disease is breast carcinoma.